Adherium Ltd (ASX: ADR) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


Adherium Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $15.00 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 5.00 billion
Earnings per share -0.004
Dividend per share N/A
Year To Date Return -25.00%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

  • Adherium Ltd (ASX: ADR)
    Latest News

    A drawing of a white rocket streaking up, indicating a surging share pirce movement
    Share Market News

    Adherium (ASX:ADR) share price rockets 53% on US FDA clearance

    The company's shares are hitting a new 6-month high...

    Read more »

    ADR ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

    About Adherium Ltd

    Adherium Ltd is engaged in the development, manufacture, and supply of its Hailie digital health technologies that address sub-optimal medication use and improve health outcomes in chronic disease. Geographically, it derives a majority of its revenue from Europe and also has a presence in New Zealand and Australia; North America, and Asia.

    ADR Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    01 Dec 2023 $0.00 $0.00 0.00% 1,001,157 $0.00 $0.00 $0.00
    29 Nov 2023 $0.00 $0.00 0.00% 500,000 $0.00 $0.00 $0.00
    28 Nov 2023 $0.00 $0.00 0.00% 40,000,000 $0.00 $0.00 $0.00
    27 Nov 2023 $0.00 $0.00 0.00% 236,100 $0.00 $0.00 $0.00
    24 Nov 2023 $0.00 $0.00 0.00% 671,000 $0.00 $0.00 $0.00
    23 Nov 2023 $0.00 $0.00 0.00% 356,258 $0.00 $0.00 $0.00
    22 Nov 2023 $0.00 $0.00 0.00% 2,172,000 $0.00 $0.00 $0.00
    21 Nov 2023 $0.00 $0.00 0.00% 2,623,000 $0.00 $0.00 $0.00
    20 Nov 2023 $0.00 $0.00 0.00% 30,000,000 $0.00 $0.00 $0.00
    17 Nov 2023 $0.00 $0.00 0.00% 109,033 $0.00 $0.00 $0.00
    16 Nov 2023 $0.00 $0.00 0.00% 271,000 $0.00 $0.00 $0.00
    10 Nov 2023 $0.00 $0.00 0.00% 1,000,000 $0.00 $0.00 $0.00
    08 Nov 2023 $0.00 $0.00 0.00% 3,363,016 $0.00 $0.00 $0.00
    06 Nov 2023 $0.00 $0.00 0.00% 280,012 $0.00 $0.00 $0.00

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    07 Aug 2023 William (Bill) Hunter Sell 300,000 $1,500
    As advised by the company. Buy back of shares due to award expiry
    07 Aug 2023 Bruce McHarrie Sell 300,000 $1,500
    As advised by the company. Buy back of shares due to award expiry
    07 Aug 2023 Jeremy Curnock-Cook Sell 300,000 $1,500
    As advised by the company. Buy back of shares due to award expiry
    12 Dec 2022 George Baran Buy 76,250,000 $254,166
    Placement. cash
    12 Dec 2022 George Baran Buy 152,500,000 $508,333
    Placement. cash

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Louis (Lou) James Panaccio Non-Executive Director Feb 2022
    Mr Panaccio is a Non-executive Director of Unison Housing Limited, VGI Health Technology Limited, NeuralDX Limited and Haemokinesis Limited. Mr Panaccio was the Chief Executive Officer and Executive Director of Melbourne Pathology, the Chief Executive Officer of Monash IVF and the Executive Chairman of Health Networks Australia.
    Dr William (Bill) Lawrence Hunter Non-Executive Director Dec 2015
    Dr Hunter has experience in commercialising medical device technologies. He co-founded Angiotech Pharmaceuticals and assumed the position of CEO when Angiotech was a venture-stage, private, pre-clinical company with less than 50 employees. He led Angiotech through its IPO and listing on the Toronto Stock Exchange and NASDAQ. Dr Hunter has over 200 patents and patent applications to his name and products in which he was an inventor or co-inventor. He is currently President and CEO of Canary Medical Inc. and formerly Correvio Pharma Corp. Dr Hunter is also a Director of Rex Bionics and an Industry Expert Advisor for BioScience Managers. He has previously served as a director of Epirus Biopharmaceuticals and Union Medtech.
    Mr Bruce Fielding McHarrie Non-Executive Director Jul 2015
    Mr McHarrie is a company director and adviser in the health and life sciences sectors with over 25 years' experience. He was formerly with Telethon Kids Institute in Perth, Western Australia, for 15 years, where his roles included Chief Financial Officer, Director of Operations and Director of Strategic Projects. Prior to joining Telethon Kids, Mr McHarrie was a Senior Manager at Deloitte in London before moving to Rothschild Asset Management as Assistant Director of the Bioscience Unit, a life sciences private equity group investing in early-stage biotechnology and healthcare companies.
    Mr Jeremy Curnock-Cook Non-Executive Director Apr 2015
    Mr Curnock Cook was head of the life science private equity team at Rothschild Asset Management in the UK and is an active investor in the Australian life science sector. At Rothschild, Mr Curnock Cook was responsible for the launch of the first dedicated biotechnology fund for the Australian market. Over his 40-year career, Mr Curnock Cook has specialised in creating value in emerging biotech enterprises, through active participation with management. He has served on over 40 boards in various roles, including chair of private and public biotechnology companies listed on NASDAQ, AMEX, LSE, TSX and ASX. He is currently Managing Director of BioScience Managers, and sits on the board of Avita Medical, Rex Bionics Pty, Humanetix Ltd, Marine Department Ltd, Cambridge Respiratory Innovations Ltd, and Sea Dragon Ltd. Mr Curnock Cook was previously a director of Bioxyne Limited and Phylogica Limited.
    Mr George Baran Non-Executive Director May 2021
    Mr Baran has over 35 years of experience in the medical device industry and serves as Executive Chair of the Trudell Medical Limited Board of Directors as well as being a significant shareholder. In addition to his role at Trudell, Mr Baran is an active investor in and Director of several medical device and e-health/connected care companies including Sensory Technologies, Mozzaz Corporation, and Sky Medical Technology Inc. He was also a lead investor and a former Director of Vanrx Phamasystems, which was recently acquired by Cytiva Life Sciences.
    Mr Brett William Tucker Company Secretary May 2023
    Mr Rick Legleiter Chief Executive Officer May 2021
    Rick Legleiter Chief Executive Officer
    Daniel Kaplon Chief Financial Officer
    Geoff Feakes Chief Technology Officer
    Brett William Tucker Company Secretary

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Phillip Asset Management Limited1 1,106,007,400 22.16%
    Trudell Medical Ltd 1,103,080,272 22.10%
    Citicorp Nominees Pty Limited 505,974,061 10.14%
    HSBC Custody Nominees (Australia) Limited 481,052,381 9.64%
    K One W One Ltd 180,503,018 3.62%
    Merrill Lynch (Australia) Nominees Pty Ltd 145,095,725 2.91%
    Neweconomy Nominees Pty Ltd <900 Account> 121,721,696 2.44%
    Brispot Nominees Pty Ltd <House Head Nominee A/C> 85,213,876 1.71%
    Warbont Nominees Pty Ltd <Unpaid Entrepot A/C> 70,000,000 1.40%
    Jmid Pty Ltd <Jam Superfund A/C> 65,000,000 1.30%
    Buttonwood Nominees Pty Ltd 60,000,000 1.20%
    UBS Nominees Pty Ltd 55,986,539 1.12%
    Andrew Rhys Jackson 50,000,000 1.00%
    One Funds Management Limited <Asia Pac Health Fund Ii A/C> 48,808,957 0.98%
    Quantamatics Pty Ltd 38,186,966 0.76%
    Summatix Pty Ltd 35,496,341 0.71%
    Adherium Esp Trustee Limited 32,183,336 0.66%
    BNP Paribas Noms (Nz) Ltd <Drp> 28,516,873 0.57%
    Planet Innovation Pty Ltd 26,666,667 0.53%
    Mr Carlsen Wilson Henry Marks + Mrs Edwina Mary Marks 25,000,000 0.50%